Lifecare ASA — Regulatory Filings 2023

May 12, 2023

Lifecare newsletter

Lifecare newsletter

Bergen, Norway 12 May 2023

Lifecare's latest updates include information of the recently finalized clinical study and the presentation of study results on the upcoming American Diabetes Association Congress in San Diego, the company's Q1 2023 report, ISO 9001 certification of Lifecare Laboratory and the progress for our planned manufacturing site in Mainz, Germany.

Read more in Lifecare's newsletter on this link:

https://us20.campaign-archive.com/?u=f0eeef8df637c6b4d457c5ead&id=a6db52caaf

ABOUT LIFECARE

Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare´s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This stock exchange announcement was published by Joacim Holter, CEO at Lifecare AS, on 12 May 2023 at 11:43 CET.